Writing the next chapter in GI health
Vedanta is advancing first-in-class Live Biotherapeutic Products (LBP) to treat serious gastrointestinal diseases using defined consortia of bacteria.
Writing the
next chapter
in GI health
Vedanta is advancing first-in-class
Live Biotherapeutic Products (LBP) to treat
serious gastrointestinal diseases
using defined consortia of bacteria.
Commitment to Patients
Gut dysbiosis is a known driver of inflammatory and infectious GI diseases. Our drugs can stimulate a range of immune responses which hold potential for the treatment of these diseases.
Inflammatory Bowel Disease
IBD occurs when the body's natural defense system mistakenly attacks healthy bowel cells. This causes inflammation and other damage that does not go away on its own.
C. difficile Infection
Clostridium difficile (C. diff), a type of bacteria, is one of the most common causes of health care-associated infections and has also emerged as a cause of community-associated infections.
Clinical Trials
Vedanta is conducting clinical trials in inflammatory bowel disease and recurrent Clostridium difficile infection to evaluate the efficacy and safety of potential drug candidates.
Advanced clinical-stage pipeline in gastrointestinal inflammation and infection
explore our pipeline
Working at Vedanta
At Vedanta Biosciences, we share a passion for groundbreaking scientific work to improve the lives of patients.